Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.
Muñoz-Unceta N, Zugazagoitia J, Manzano A, Jiménez-Aguilar E, Olmedo ME, Cacho JD, Oliveira J, Dómine M, Ortega-Morán L, Aguado C, Luna AM, Fernández L, Pérez J, Font C, Salvador C, Corral J, Benítez G, Ros S, Biosca M, Calvo V, Martínez J, Sánchez-Cánovas M, López R, Sereno M, Mielgo X, Aparisi F, Carmona M, Carrión R, Ponce-Aix S, Soares M, Martínez-Salas I, García-Morillo M, Juan-Vidal O, Blasco A, Muñoz AJ, Paz-Ares L; Grupo de trombosis y cáncer SEOM. Muñoz-Unceta N, et al. Eur J Cancer. 2020 Dec;141:193-198. doi: 10.1016/j.ejca.2020.10.002. Epub 2020 Nov 7. Eur J Cancer. 2020. PMID: 33166862
Durvalumab in NSCLC: latest evidence and clinical potential.
Muñoz-Unceta N, Burgueño I, Jiménez E, Paz-Ares L. Muñoz-Unceta N, et al. Ther Adv Med Oncol. 2018 Oct 11;10:1758835918804151. doi: 10.1177/1758835918804151. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 30344651 Free PMC article. Review.
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
Rivera F, Izquierdo-Manuel M, García-Alfonso P, Martínez de Castro E, Gallego J, Limón ML, Alsina M, López L, Galán M, Falcó E, Manzano JL, González E, Muñoz-Unceta N, López C, Aranda E, Fernández E, Jorge M, Jiménez-Fonseca P. Rivera F, et al. Among authors: munoz unceta n. Eur J Cancer. 2021 Mar;145:158-167. doi: 10.1016/j.ejca.2020.12.005. Epub 2021 Jan 20. Eur J Cancer. 2021. PMID: 33485079 Clinical Trial.
Prevalence, Clinical Characteristics, and Management of Episodic Dyspnea in Advanced Lung Cancer Outpatients: A Multicenter Nationwide Study-The INSPIRA-DOS Study.
Julià-Torras J, Almeida Felipe JM, Gándara Del Castillo Á, González-Barboteo J, Forero D, Alegre S, Cuervo-Pinna MÁ, Serna J, Muñoz-Unceta N, Alonso-Babarro A, Miró Catalina Q, Moreno-Alonso D, Porta-Sales J. Julià-Torras J, et al. Among authors: munoz unceta n. J Palliat Med. 2022 Aug;25(8):1197-1207. doi: 10.1089/jpm.2021.0562. Epub 2022 Feb 23. J Palliat Med. 2022. PMID: 35196465
Risk factors associated with Clostridium difficile infection in adult oncology patients.
Rodríguez Garzotto A, Mérida García A, Muñoz Unceta N, Galera Lopez MM, Orellana-Miguel MÁ, Díaz-García CV, Cortijo-Cascajares S, Cortes-Funes H, Agulló-Ortuño MT. Rodríguez Garzotto A, et al. Among authors: munoz unceta n. Support Care Cancer. 2015 Jun;23(6):1569-77. doi: 10.1007/s00520-014-2506-7. Epub 2014 Nov 20. Support Care Cancer. 2015. PMID: 25410088
Neoadjuvant chemotherapy with dose-dense MVAC in muscle-invasive bladder cancer: a tertiary center experience.
Serrano M, Muñoz-Unceta N, Alonso LA, Azueta A, Gutiérrez Baños JL, Ferreira L, Domínguez M, Torres Zurita A, Ballestero R, Cacho D, López-Brea M, Sotelo M, Campos-Juanatey F, Ramos Barseló E, Duran I. Serrano M, et al. Among authors: munoz unceta n. Clin Transl Oncol. 2024 Feb;26(2):549-553. doi: 10.1007/s12094-023-03277-4. Epub 2023 Aug 11. Clin Transl Oncol. 2024. PMID: 37566343
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
Rivera F, Romero C, Jimenez-Fonseca P, Izquierdo-Manuel M, Salud A, Martínez E, Jorge M, Arrazubi V, Méndez JC, García-Alfonso P, Reboredo M, Barriuso J, Muñoz-Unceta N, Jimeno R, López C. Rivera F, et al. Among authors: munoz unceta n. Cancer Chemother Pharmacol. 2019 Jun;83(6):1175-1181. doi: 10.1007/s00280-019-03820-7. Epub 2019 Mar 29. Cancer Chemother Pharmacol. 2019. PMID: 30927036 Free PMC article. Clinical Trial.
Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
Rivera F, Romero C, Jimenez-Fonseca P, Izquierdo-Manuel M, Salud A, Martínez E, Jorge M, Arrazubi V, Méndez JC, García-Alfonso P, Reboredo M, Barriuso J, Muñoz-Unceta N, Jimeno R, López C. Rivera F, et al. Among authors: munoz unceta n. Cancer Chemother Pharmacol. 2019 Dec;84(6):1365. doi: 10.1007/s00280-019-03964-6. Cancer Chemother Pharmacol. 2019. PMID: 31587095 Free PMC article.